| 1 |
35184709 | Inhibition of Cytochrome P450 Enzyme and Drug-Drug Interaction Potential of Acid Reducing Agents Used in Management of CDK Inhibitors for Breast Cancer Chemotherapy. | 2022 |
1 |
| 2 |
34312304 | Icotinib Induces Mechanism-Based Inactivation of Recombinant Human CYP3A4/5 Possibly via Heme Destruction by Ketene Intermediate. | 2021 Oct |
2 |
| 3 |
32244772 | Structure-Based Site of Metabolism (SOM) Prediction of Ligand for CYP3A4 Enzyme: Comparison of Glide XP and Induced Fit Docking (IFD). | 2020 Apr 1 |
1 |
| 4 |
32664320 | The Grapefruit Effect: Interaction between Cytochrome P450 and Coumarin Food Components, Bergamottin, Fraxidin and Osthole. X-ray Crystal Structure and DFT Studies. | 2020 Jul 10 |
1 |
| 5 |
32712589 | No effect of lipoic acid on catalytic activity of cytochrome P450 3A4. | 2020 Jul 27 |
1 |
| 6 |
30627802 | Sorafenib N-Oxide Is an Inhibitor of Human Hepatic CYP3A4. | 2019 Jan 9 |
1 |
| 7 |
30676743 | Interaction of Human Drug-Metabolizing CYP3A4 with Small Inhibitory Molecules. | 2019 Feb 19 |
1 |
| 8 |
31339834 | Comparison of Steroid Hormone Hydroxylations by and Docking to Human Cytochromes P450 3A4 and 3A5. | 2019 |
3 |
| 9 |
31510073 | Molecular Dynamics Simulation Framework to Probe the Binding Hypothesis of CYP3A4 Inhibitors. | 2019 Sep 10 |
1 |
| 10 |
29362093 | Functional characterization of naturally occurring wild soybean mutant (sg-5) lacking astringent saponins using whole genome sequencing approach. | 2018 Feb |
1 |
| 11 |
29991575 | Comparison of Antifungal Azole Interactions with Adult Cytochrome P450 3A4 versus Neonatal Cytochrome P450 3A7. | 2018 Sep |
1 |
| 12 |
30115511 | Amelioration of mechanism-based inactivation of CYP3A4 by a H-PGDS inhibitor. | 2018 Oct 1 |
1 |
| 13 |
28616684 | Influence of Ethanol on Darunavir Hepatic Clearance and Intracellular PK/PD in HIV-Infected Monocytes, and CYP3A4-Darunavir Interactions Using Inhibition and in Silico Binding Studies. | 2017 Sep |
1 |
| 14 |
28919040 | Heme Binding Biguanides Target Cytochrome P450-Dependent Cancer Cell Mitochondria. | 2017 Oct 19 |
3 |
| 15 |
28986474 | Digging Deeper into CYP3A Testosterone Metabolism: Kinetic, Regioselectivity, and Stereoselectivity Differences between CYP3A4/5 and CYP3A7. | 2017 Dec |
4 |
| 16 |
26741368 | Effect of Methamphetamine on Spectral Binding, Ligand Docking and Metabolism of Anti-HIV Drugs with CYP3A4. | 2016 |
2 |
| 17 |
26939024 | Substrate Dependent Native Luminescence from Cytochromes P450 3A4, 2C9, and P450cam. | 2016 Mar 31 |
1 |
| 18 |
27469000 | Analysis of Mechanism-Based Inhibition of CYP 3A4 by a Series of Fluoroquinolone Antibacterial Agents. | 2016 Oct |
2 |
| 19 |
27530542 | Inhibition of cytochrome P450 3A by acetoxylated analogues of resveratrol in in vitro and in silico models. | 2016 Aug 17 |
1 |
| 20 |
25499431 | Investigating the binding interactions of the anti-Alzheimer's drug donepezil with CYP3A4 and P-glycoprotein. | 2015 Jan 15 |
1 |
| 21 |
25651456 | In silico prediction of the site of oxidation by cytochrome P450 3A4 that leads to the formation of the toxic metabolites of pyrrolizidine alkaloids. | 2015 Apr 20 |
1 |
| 22 |
26124807 | Drug-drug interation prediction between ketoconazole and anti-liver cancer drug Gomisin G. | 2015 Jun |
1 |
| 23 |
26211584 | Molecular docking of chemotherapeutic agents to CYP3A4 in non-small cell lung cancer. | 2015 Jul |
1 |
| 24 |
24484539 | Comparison of catalytic properties of cytochromes P450 3A4 and 3A5 by molecular docking simulation. | 2014 |
3 |
| 25 |
24805065 | Ritonavir analogues as a probe for deciphering the cytochrome P450 3A4 inhibitory mechanism. | 2014 |
1 |
| 26 |
23404373 | Metabolism-dependent inhibition of CYP3A4 by lapatinib: evidence for formation of a metabolic intermediate complex with a nitroso/oxime metabolite formed via a nitrone intermediate. | 2013 May |
1 |
| 27 |
23586711 | Pyridine-substituted desoxyritonavir is a more potent inhibitor of cytochrome P450 3A4 than ritonavir. | 2013 May 9 |
1 |
| 28 |
23886699 | The effect of ritonavir on human CYP2B6 catalytic activity: heme modification contributes to the mechanism-based inactivation of CYP2B6 and CYP3A4 by ritonavir. | 2013 Oct |
3 |
| 29 |
24312617 | Identifying cytochrome p450 functional networks and their allosteric regulatory elements. | 2013 |
1 |
| 30 |
21997754 | Quantum mechanically derived AMBER-compatible heme parameters for various states of the cytochrome P450 catalytic cycle. | 2012 Jan 15 |
1 |
| 31 |
22106171 | Stereospecific metabolism of itraconazole by CYP3A4: dioxolane ring scission of azole antifungals. | 2012 Mar |
3 |
| 32 |
22113809 | Binding free energies of inhibitors to iron porphyrin complex as a model for Cytochrome P450. | 2012 Apr |
4 |
| 33 |
22157006 | Structural and mechanistic insights into the interaction of cytochrome P4503A4 with bromoergocryptine, a type I ligand. | 2012 Jan 27 |
1 |
| 34 |
22187487 | Excretion, metabolism, and pharmacokinetics of 1-(8-(2-chlorophenyl)-9-(4-chlorophenyl)-9H-purin-6-yl)-4-(ethylamino)piperidine-4-carboxamide, a selective cannabinoid receptor antagonist, in healthy male volunteers. | 2012 Mar |
1 |
| 35 |
22197672 | Prediction of sites of metabolism in a substrate molecule, instanced by carbamazepine oxidation by CYP3A4. | 2012 Jan 15 |
1 |
| 36 |
22513143 | Role of human CYP3A4 in the biotransformation of sorafenib to its major oxidized metabolites. | 2012 Jul 15 |
1 |
| 37 |
22677141 | Conformational dynamics of CYP3A4 demonstrate the important role of Arg212 coupled with the opening of ingress, egress and solvent channels to dehydrogenation of 4-hydroxy-tamoxifen. | 2012 Oct |
2 |
| 38 |
22896728 | Metabolism, excretion, and pharmacokinetics of ((3,3-difluoropyrrolidin-1-yl)((2S,4S)-4-(4-(pyrimidin-2-yl)piperazin-1-yl)pyrrolidin-2-yl)methanone, a dipeptidyl peptidase inhibitor, in rat, dog and human. | 2012 Nov |
1 |
| 39 |
23016756 | Reaction of human cytochrome P450 3A4 with peroxynitrite: nitrotyrosine formation on the proximal side impairs its interaction with NADPH-cytochrome P450 reductase. | 2012 Dec 17 |
2 |
| 40 |
21212239 | Comparison of the inhibitory profiles of itraconazole and cimetidine in cytochrome P450 3A4 genetic variants. | 2011 Apr |
1 |
| 41 |
21266595 | Sorafenib and sunitinib, two anticancer drugs, inhibit CYP3A4-mediated and activate CY3A5-mediated midazolam 1'-hydroxylation. | 2011 May |
1 |
| 42 |
21447734 | Mechanism-based inactivation of cytochrome P450 3A4 by mibefradil through heme destruction. | 2011 Jul |
3 |
| 43 |
19797609 | Exploration of catalytic properties of CYP2D6 and CYP3A4 through metabolic studies of levorphanol and levallorphan. | 2010 Jan |
2 |
| 44 |
19923256 | Identification of novel substrates for human cytochrome P450 2J2. | 2010 Feb |
1 |
| 45 |
20624855 | Mechanism-based inactivation of cytochrome P450 3A4 by lapatinib. | 2010 Oct |
1 |
| 46 |
19364136 | Screening of type I and II drug binding to human cytochrome P450-3A4 in nanodiscs by localized surface plasmon resonance spectroscopy. | 2009 May 15 |
1 |
| 47 |
19414330 | Flexible structure of cytochrome P450: promiscuity of ligand binding in the CYP3A4 heme pocket. | 2009 Mar |
2 |
| 48 |
18092806 | Nile Red is a fluorescent allosteric substrate of cytochrome P450 3A4. | 2008 Jan 15 |
1 |
| 49 |
18096676 | CYP3A4-Mediated carbamazepine (CBZ) metabolism: formation of a covalent CBZ-CYP3A4 adduct and alteration of the enzyme kinetic profile. | 2008 Mar |
2 |
| 50 |
17198380 | Mechanism of interactions of alpha-naphthoflavone with cytochrome P450 3A4 explored with an engineered enzyme bearing a fluorescent probe. | 2007 Jan 9 |
1 |